To check this hypothesis, we treated the private and larotrectinib-resistant PDXs established from Individual 1 with larotrectinib, trametinib or a combined mix of both
To check this hypothesis, we treated the private and larotrectinib-resistant PDXs established from Individual 1 with larotrectinib, trametinib or a combined mix of both. Genomics at the next Link: http://cbioportal.org/msk-impact.…